ArticleJournal of hepatocellular carcinoma2023

Efficacy and Safety of Tyrosine Kinase Inhibitors Alone or Combination with Programmed Death-1 Inhibitors in Treating of Hepatitis C-Related Hepatocellular Carcinoma.

Jin Lei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.